RT Journal Article
T1 Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization
A1 Vega, A.
A1 Jimenez-Rodriguez, T-W
A1 Barranco, R.
A1 Bartra, J.
A1 Dieguez, M. C.
A1 Dona, I
A1 Fernandez-Rivas, M.
A1 Gandolfo-Cano, M.
A1 Gastaminza-Lasarte, G.
A1 Gonzalez-Mancebo, E.
A1 Caballer, B. de la Hoz
A1 Sanchez-Morillas, L.
A1 Torres, M. J.
A1 Berges-Gimeno, M. P.
A1 Munoz-Cano, R.
K1 Drug allergy
K1 Drug hypersensitivity
K1 Desensitization
K1 Chemotherapy
K1 Drug challenge
K1 Monoclonal antibodies
K1 Successful oral desensitization
K1 Hereditary alpha-tryptasemia
K1 Rapid drug desensitization
K1 Basophil activation test
K1 Stevens-johnson-syndrome
K1 Monoclonal-antibodies
K1 Ige desensitization
K1 Skin-test
K1 Carboplatin hypersensitivity
K1 General-considerations
AB Rapid drug desensitization has enabled first-line therapies in patients with drug hypersensitivity reactions to chemotherapeutic drugs including monoclonal antibodies. Desensitization is a safe and highly effective procedure, not only for IgE-mediated reactions, but also for those mediated by non-IgE mechanisms. The likelihood of breakthrough reactions during desensitization is low, and most are mild; in fact, moderate-to-severe reactions are infrequent. In this document, 16 allergy departments belonging to the Spanish research network ARADyAL present a review of the available scientific evidence and provide general guidelines for the diagnosis and management of drug hypersensitivity reactions to chemotherapeutic drugs and monoclonal antibodies. Emphasis is placed on the desensitization procedure.
PB Esmon publicidad s a, dept allergy & clin immunol, clin univ navarra
SN 1018-9068
YR 2021
FD 2021-01-01
LK https://hdl.handle.net/10668/24474
UL https://hdl.handle.net/10668/24474
LA en
DS RISalud
RD Apr 6, 2025